Trials / Completed
CompletedNCT00113113
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Phase I Study of Rubitecan (RFS 2000) in the Treatment of Cancer Patients With Organ Dysfunction
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Astex Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Cancer patients with liver or renal dysfunction will be treated with rubitecan capsules to define the maximum tolerated dose and the dose-limiting toxicity in this patient population, and to perform pharmacokinetic studies of rubitecan in this patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rubitecan |
Timeline
- Start date
- 2001-08-01
- First posted
- 2005-06-06
- Last updated
- 2024-08-02
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00113113. Inclusion in this directory is not an endorsement.